A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses.
about
Enhancing oral vaccine potency by targeting intestinal M cellsImmune mechanisms of protection: can adjuvants rise to the challenge?Pros and Cons of Antigen-Presenting Cell Targeted Tumor VaccinesConsiderations for the rapid deployment of vaccines against H7N9 influenza.Different arms of the adaptive immune system induced by a combination vaccine work in concert to provide enhanced clearance of influenza.Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.Lipopeptide vaccines illustrate the potential role of subtype-crossreactive T cells in the control of highly virulent influenzaRole of CD8(+) T-cell immunity in influenza infection: potential use in future vaccine development.Cross-protective immunity to influenza A viruses.Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine.The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus.Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity.Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptorsLinear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunityThe TLR2 Binding Neisserial Porin PorB Enhances Antigen Presenting Cell Trafficking and Cross-presentation.Robust immune responses elicited by a fully synthetic three-component vaccine.Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonistsDifferential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis.Lipid motif of a bacterial antigen mediates immune responses via TLR2 signaling.Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationshipTh-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection.TLR-based immune adjuvants.Combinatorial contextualization of peptidic epitopes for enhanced cellular immunity.Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responsesThe magnitude of local immunity in the lungs of mice induced by live attenuated influenza vaccines is determined by local viral replication and induction of cytokinesDeveloping vaccines against minor capsid antigen L2 to prevent papillomavirus infection.A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building.A novel exopolysaccharide from the biofilm of Thermus aquaticus YT-1 induces the immune response through Toll-like receptor 2.Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection.Characterization of a branched lipopeptide candidate vaccine against influenza A/Puerto Rico 8/34 which is recognized by human B and T-cell immune responses.Peptide amphiphile micelles self-adjuvant group A streptococcal vaccinationSynthesis and characterisation of self-assembled and self-adjuvanting asymmetric multi-epitope lipopeptides of ovalbumin.Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide.A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infectionFrom mice to humans - murine intelligence for human CD8+ T cell vaccine design.Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyMammalian Toll-like receptors: to immunity and beyond.Memory cytolytic T-lymphocytes: induction, regulation and implications for vaccine design.Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B.Delivery of Chlamydia vaccines.
P2860
Q21089613-F7790372-DA91-4F37-93FE-6D01E5F7A7FEQ21245319-A355D8F8-4F54-4E3E-81D1-9EFCAD807E7AQ27013679-9D5563D7-3D59-4FAA-9E1D-69FAC7E11B42Q30364635-1110AFC3-98F8-43CD-B3D7-2CF7FC11CA61Q30369956-CCB1E4FD-AD51-4DBA-B963-DD9539D02EC0Q30375714-1765D002-3251-4CB0-990F-563676A56B67Q30379213-709A67F5-E9B7-4029-A1E8-0623C49999DEQ30389274-9146F2CC-D218-407A-B61A-B098BBF987BCQ30396399-CE5B48CE-A268-431B-952D-F220D3D2BFA3Q30398068-5A75378C-7B52-45E9-B5F8-D28366B4FA5BQ30423530-089BAFA1-ED7D-445C-8049-B9E7E6CF07D9Q30476891-5337050B-6219-44CB-B06C-A75F02623B8EQ33591916-688934BE-F165-45E3-A911-5E1AF2969357Q33614657-C684F4EB-BD55-4C35-9F62-D60B515CF203Q33673210-FA59097D-AA33-45C1-8C80-7EDA6B31CCBAQ33721005-5171C3F3-FBC8-41DF-825F-12DBB1A1A6B4Q33721641-05C5ED93-8CA6-48E5-B7BF-66330609B1C1Q33784386-02C830D3-DE58-4C21-AC55-B3591E4A5CE3Q33911347-C70232DE-C249-401B-BF08-E9760135AAC2Q34131142-4B21606A-9DA7-471E-A4B0-B1A9A35FA615Q34228659-B9B25958-5073-4552-BF8C-843EF926CEC8Q34400322-1AC9D6E4-6F75-4B9D-876E-A7BCB3B451ADQ34400527-6D444F99-40C9-407F-AD31-235DC11E6740Q34455275-9340870E-3B91-409C-BCC7-5F075221CB50Q34458066-0FBD7672-FD51-4360-A614-202BE31387AEQ34786808-5C6D5E6D-4FA6-4CF7-9C00-6F10FDC17410Q34787042-F2A03B44-980A-43C9-BF77-17191370E54FQ34978959-5A90B31C-53D7-4EA0-A46C-57B5B7B52EC7Q35008279-78E9A559-1C47-4FA3-B445-B05316F5C789Q35133760-C906B7C2-CEA5-4B0A-8F47-936929343A65Q35192883-F60903C9-ED22-466E-A6CF-B4C59B675EFCQ35423378-B8C10D56-4DB2-4025-9F7F-7C95D7E19DE8Q35800918-425B6687-293A-478B-8F22-D5361B1CA075Q35920476-59359E26-D11A-42CA-90D9-52413CC6FAF6Q36065972-386858A8-0B6F-4300-843C-71A1CFB6BF2FQ36116250-2E59CAE7-6A89-4A05-8CE9-8BB3C8E38D1AQ36149113-E451D163-3D6E-49EA-B69A-021335764F65Q36284560-16E9BBC9-84C4-40BF-A827-A72A816AC8EFQ36313996-7595CCCD-1711-4707-AF29-06C3BD2E9C63Q36316798-A6D2C290-A1DF-4F26-8BB4-20A823F339A0
P2860
A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 October 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A totally synthetic vaccine of ...... or cytotoxic T cell responses.
@en
A totally synthetic vaccine of ...... or cytotoxic T cell responses.
@nl
type
label
A totally synthetic vaccine of ...... or cytotoxic T cell responses.
@en
A totally synthetic vaccine of ...... or cytotoxic T cell responses.
@nl
prefLabel
A totally synthetic vaccine of ...... or cytotoxic T cell responses.
@en
A totally synthetic vaccine of ...... or cytotoxic T cell responses.
@nl
P2093
P2860
P50
P921
P356
P1476
A totally synthetic vaccine of ...... or cytotoxic T cell responses.
@en
P2093
Christina Cheers
Corey Smith
Georgia Deliyannis
Weiguang Zeng
Yuk Fai Lau
P2860
P304
15440-15445
P356
10.1073/PNAS.0406740101
P407
P577
2004-10-15T00:00:00Z